Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Gala vs Noom

Gala costs $50 less a month, and both sell semaglutide and tirzepatide.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Gala logo

Gala

8.7
★★★★☆4.4/5

Best for: moving between compounded and brand without changing seller

Visit Gala →
VS
Noom logo

Noom

6.7
★★★☆☆3.4/5

Best for: coaching bundled into the price rather than sold separately

Visit Noom →

If you are choosing between Gala and Noom, the first difference is cost: Gala is $50 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Gala leads our six-part score, 8.7 to 6.7.

Gala vs Noom price

Gala is the cheaper way in: $149 a month against $199 a month at Noom. That is $50 less each month (25% lower), or about $600 over a year of treatment.

Drug by drug: Semaglutide is cheaper at Gala ($179 a month vs $199 a month); tirzepatide is cheaper at Gala ($149 a month vs $349 a month).

Medications and formats

Both sell semaglutide and tirzepatide.

On format they match: each offers compounded injections and brand-name pens.

Where each one treats patients

Gala lists 50 states, and Noom does not publish where it ships.

Pricing

Gala

Compounded GLP-1 (all doses)Compounded
$179$129/mo
Save 28% right now
semaglutide

$179/mo on a yearly subscription, all doses included. Gala's FAQ says 'starting at just $199 per month (with a 3-month plan).' A promo page offers 'starting at $129/month with $120 off your first shipment' on monthly, 3-, 6- and 12-month plans. Exact plan prices appear only after the intake questionnaire.

Compounded GLP-1/GIP (all doses)Compounded
$179/mo
tirzepatide

$179/month on a yearly subscription, all doses included; the $120-off-first-shipment promo applies. Tirzepatide plan prices are shown only after intake.

Microdosing GLP-1/GIPCompounded
$149/mo
tirzepatide

$149/month, yearly subscription; 'Low-dose GLP-1/GIP for sustained energy, sleep and metabolic balance.'

Ozempic (brand)Brand-name
$1299/mo
semaglutide

'Ozempic® Brand-name semaglutide $1,299/month' — unchanged. Wegovy pill still 'Coming soon / Pricing at launch' (not a priced row).

Noom

GLP-1Rx Program — brand semaglutide (Wegovy/Ozempic)Brand-name
$349/mo
semaglutide
GLP-1Rx Program — brand tirzepatide (Zepbound/Mounjaro)Brand-name
$349/mo
tirzepatide
Microdose GLP-1Rx — compounded semaglutideCompounded
$199/mo
semaglutide

What each price covers

Both prices cover the clinician visit.

Gala's price also covers the medication itself and shipping, which Noom does not claim.

Noom's price also covers coaching, which Gala does not claim.

Gala is silent on lab work and coaching.

Noom is silent on the medication itself, shipping and lab work.

That matters most for the drug: unless Noom confirms otherwise, budget for medication on top of its listed price.

Gala

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Noom

Covered by the monthly price

Medication

Not stated

Clinician visits

In the price

Shipping

Not stated

Lab work

Not stated

Coaching

In the price

Where each one scores higher

Overall, Gala scores 8.7 and Noom 6.7 out of 10.

Gala is stronger on value (8.7 vs 4.4), trust & safety (7.5 vs 6.5), accessibility (10.0 vs 5.0) and support (7.0 vs 4.0).

Effectiveness and user experience are within half a point.

How we score

Gala

8.7/10

Overall

Noom

6.7/10

Value25%

8.7A
vs
B
4.4

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.5A
vs
B
6.5

Accessibility10%

10.0A
vs
B
5.0

Support10%

7.0A
vs
B
4.0

FDA warning letters

Neither Gala nor Noom has an FDA warning letter on record with us.

Features & Coverage

FeatureGalaNoom
Starting Price✓$149/mo$199/mo
Features✓7 features2 features
States Available50Not disclosed
Compounded✓ Yes✓ Yes
Brand Name✓ Yes✓ Yes
FSA/HSA Accepted——
FDA Warning LettersNoneNone

About Gala

A yearly subscription is the format: compounded semaglutide and compounded tirzepatide are sold that way, with a cheaper microdosing program beside them and brand-name Ozempic on the same menu. The corporate name is AI Coaching Inc., which does business as Gala GLP-1 and is incorporated in Delaware. Providers licensed in every one of the 50 states, plus shipping at no cost, are what the marketing site claims. A Wegovy pill taken orally is flagged as coming soon.

Read our full Gala review →

About Noom

Noom is a behavioral weight loss app. It also prescribes GLP-1 medications through Noom Med.

Read our full Noom review →

Pros & Cons

Gala

What we like

  • Semaglutide costs $179 a month, close to the $184 median for compounded semaglutide across the sellers we compare
  • Tirzepatide costs $149 a month, 40% below the $250 median for compounded tirzepatide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price stays the same as your dose goes up
  • The monthly price includes the medication, clinician visits and shipping
  • Serves all 50 states
  • We found no FDA warning letters issued to Gala

Watch-outs

  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Noom

What we like

  • Semaglutide costs $199 a month, close to the $184 median for compounded semaglutide across the sellers we compare
  • Tirzepatide costs $349 a month, 72% below the $1249 median for brand-name tirzepatide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes clinician visits and coaching
  • We found no FDA warning letters issued to Noom

Watch-outs

  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Gala

Gala wins this one, 8.7 to 6.7, above all for moving between compounded and brand without changing seller. It also costs $50 less each month than Noom. Noom fits better if coaching bundled into the price rather than sold separately is your priority.

Choose Gala if…

You want moving between compounded and brand without changing seller and an opening price near $149 a month.

Choose Noom if…

You want coaching bundled into the price rather than sold separately and an opening price near $199 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.3

RNK Health

An oral route if you will not self-inject

9.2

He & She MD

Starting below a standard dose, with microdose tiers

5.9

Wellorithm

Compounded semaglutide at $247/month

Gala vs Noom: FAQ

Gala. It starts at $149 a month; Noom starts at $199 a month, $50 more per month.
Yes, both sell semaglutide and tirzepatide.
Gala lists 50 states; Noom does not publish where it ships. Confirm your state before paying.
Both include the clinician visit. Only Gala includes the medication itself and shipping. Only Noom includes coaching.
Gala has none. Noom has none.
Gala pays us a commission on sign-ups through our links; Noom does not. Scores are computed the same way for both.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.